CLINICAL TRIALS PROFILE FOR VACTOSERTIB
✉ Email this page to a colleague
Clinical Trials for Vactosertib
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT02160106 ↗ | First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors | Completed | National OncoVenture | Phase 1 | The phase I dose escalation study will investigate the safety, tolerability, and pharmacokinetics of the TGF-β pathway inhibitor TEW 7197 in subjects with advanced, refractory solid tumors. |
NCT02160106 ↗ | First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors | Completed | MedPacto, Inc. | Phase 1 | The phase I dose escalation study will investigate the safety, tolerability, and pharmacokinetics of the TGF-β pathway inhibitor TEW 7197 in subjects with advanced, refractory solid tumors. |
NCT03074006 ↗ | Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS | Completed | MedPacto, Inc. | Phase 1 | This is a prospective, open-label, multicenter, phase 1/2 study of TEW-7197 in patients with low and intermediate risk of myelodysplastic syndrome (MDS). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Vactosertib
Condition Name
Clinical Trial Locations for Vactosertib
Trials by Country
Clinical Trial Progress for Vactosertib
Clinical Trial Phase
Clinical Trial Sponsors for Vactosertib
Sponsor Name